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Objective: Reactive oxygen species have been shown to contribute to
myocardial stress in patients undergoing cardiac surgery, as demonstrated
by myocardial 8-iso-prostaglandin-F2 and nitrotyrosine formation. We
hypothesized that the reactive oxygen species scavenger N-acetylcysteine
attenuates reactive oxygen species–mediated myocardial stress in patients
undergoing cardiac surgery.
Methods: Forty patients undergoing coronary artery surgery (mean age 
SD, 66  9 years; 9 women and 31 men) were randomized to receive
either N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime
followed by infusion at 20 mg  kg1  h1, n  20) or placebo (n  20).
Patients and clinical staff were blinded to group assignment. Transmural
left ventricular biopsy specimens collected before and at the end of
cardiopulmonary bypass were subjected to immunocytochemical staining
against 8-iso-prostaglandin-F2 (primary measure) as an indicator for reactive
oxygen species–mediated lipid peroxidation and nitrotyrosine (coprimary measure)
as a marker for peroxynitrite-mediated tissue injury. Cardiomyocyte staining was
quantitatively determined by using densitometry (in gray units). Global left ven-
tricular function was measured on the basis of fractional area of contraction by using
transesophageal echocardiography.
Results: Patient characteristics in both groups were comparable. The change in left
ventricular cardiomyocyte staining (end of cardiopulmonary bypass  before car-
diopulmonary bypass) differed significantly between groups for both primary mea-
sures: 8-iso-prostaglandin-F2, 1.8  7.5 gray units (mean  SD, N-acetylcys-
teine group) versus 5.0  4.1 gray units (placebo group; 95% confidence interval,
2.6-11.0, P  .003); nitrotyrosine, 6.4  10.0 gray units (N-acetylcysteine group)
versus 9.2  8.4 gray units (placebo group; 95% confidence interval, 9.4-21.7, P 
.001). Hemodynamics and clinical outcomes were comparable in both groups.
Conclusions: Reactive oxygen species scavenging with N-acetylcysteine attenuates
myocardial oxidative stress in the hearts of patients subjected to cardiopulmonary
bypass and cardioplegic arrest.
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Reactive oxygen species (ROS), such as hy-droxyl radical (OH), superoxide radical(O2), hydrogen peroxide (H2O2), and per-oxynitrite (ONOO), the product of nitricoxide (NO) binding to O2, are thought tomediate the reperfusion injury that charac-
terizes metabolic, structural, and functional (stunning) myo-
cardial damage associated with experimental myocardial
ischemia and reperfusion.1-3 Clinical studies have provided
indirect evidence for ROS-mediated stress, such as malon-
dialdehyde and lipid hydroxylperoxidase determination in
the blood of patients with acute myocardial infarction4 or
those subjected to percutaneous transluminal coronary an-
gioplasty5,6 or coronary artery bypass surgery.7 We have
recently provided direct evidence for ROS-mediated myo-
cardial stress associated with ischemia and reperfusion be-
cause we demonstrated both 8-iso-prostaglandin-F2 and
nitrotyrosine formation in left ventricular (LV) biopsy spec-
imens of patients subjected to cardioplegic arrest.8 8-Iso-
prostaglandin-F2 is the stable end product of arachidonic
acid oxidation generated by ROS attacks on membrane
phospholipids.6,9 Nitrotyrosine represents the stable end
product of cell membrane protein–bound tyrosine nitration
by ONOO.10,11 These data indicate the clinical relevance
of ROS-mediated oxidative stress associated with ischemia
and reperfusion and imply a rational basis for ROS scaven-
gers as adjuncts to reperfusion strategies.
Although numerous experimental investigations have
demonstrated that ROS scavenging attenuates myocardial
ischemia-reperfusion injury,1 only a few clinical studies
have addressed their ability to ameliorate myocardial injury
associated with cardiopulmonary bypass (CPB) and car-
dioplegic arrest. For example, pretreatment with allopurinol
either alone or in combination with vitamins E and C has
been suggested to improve patient outcome after coronary
artery surgery by reducing the level of plasma ROS activ-
ity7,12 or to improve neurocardiac protection in high-risk
pediatric cardiac surgery with deep hypothermic circulatory
arrest.13 Menasche and colleagues14 showed that the ROS-
scavenging iron chelator deferoxamine reduced the poly-
morphonuclear neutrophil oxidative responsivness, and
Andersen and associates15 demonstrated that the antioxidant
and ROS scavenger N-acetylcysteine (NAC) reduced the
neutrophil oxidative burst response in patients subjected to
CPB and cardioplegic arrest. However, none of these stud-
ies directly investigated the effect of ROS scavenging on
myocardial tissue alterations.
Therefore the purpose of our randomized, double-blind,
controlled clinical trial was to compare the effects of NAC
versus placebo on myocardial 8-iso-prostaglandin-F2 and
nitrotyrosine formation as indicators for direct ROS-medi-
ated myocardial alterations in the hearts of patients sub-
jected to coronary artery surgery during CPB.8 We chose to
use NAC, a precursor of reduced glutathione, because of its
properties to both enhance intracellular glutathione synthe-
sis and directly scavenge ROS.16 NAC has been in clinical
use for more than 30 years, primarily as a mucolytic, and is
the gold standard for treatment of acetaminophen poison-
ing.16 In addition, NAC has recently been shown to reduce
ROS-induced renal dysfunction in patients subjected to
radiographic contrast agents.17
Materials and Methods
Patients
After approval by the University of Cologne Human Ethics Com-
mittee, written informed consent was obtained from each patient
during the preoperative interview. Forty patients (9 women and 31
men) scheduled for elective or urgent coronary artery bypass
surgery (Table 1) were randomized into either the NAC group (n
 20) or the placebo group (n  20) according to a computer-
generated allocation list (randomly permuted blocks of random
size) provided by the Department for Medical Statistics, Informat-
ics, and Epidemiology, University of Cologne. NAC (Fluimucil)
and placebo were supplied in identical-looking glass vials contain-
ing either 5 g of NAC per 50 mL or isotonic sodium chloride
solution. The vials were sequentially numbered according to the
random list and were supplied by the Pharmacy of the University
of Cologne. Patients in the NAC group received 100 mg of NAC
per kilogram of body weight into the CPB prime, followed by
intravenous infusion at 20 mg of NAC per kilogram of body
weight per hour until the end of CPB, a regimen similar to that
clinically used by Andersen and associates.15 The rationale for
administering NAC into the CPB prime and throughout CPB as
opposed to adding it to cardioplegia alone was 2-fold: first, we
administered NAC before cardioplegia because of its property to
enhance intracellular glutathione synthesis,16 and second, we in-
tended to have systemic NAC concentrations at the time of mas-
sive ROS production (ie, myocardial reperfusion after aortic cross-
clamp release) because of NAC’s property to directly scavenge
ROS.16 Patients in the placebo group received equivalent amounts
of placebo. The flow chart depicting the trial phases according to
the Consolidated Standards of Reporting Trials (CONSORT) state-
ment18 is shown in Figure 1. Patients were subjected to CPB at
32°C to 34°C, the aorta was crossclamped, and myocardial revas-
cularization was performed during cardioplegic arrest by using
single-shot, antegrade, cold (4°C) crystalloid Bretschneider car-
dioplegia (Custodiol, Dr Ko¨hler Chemie).
Clinical Protocol
After anesthesia induction and standard hemodynamic monitoring,
including Swan-Ganz pulmonary artery catheterization, a 5-MHz
transesophageal echocardiography (TEE) probe was placed to pro-
vide a LV short-axis image at the midpapillary level. From the
TEE recordings, we derived the fractional area of contraction
(FAC) as a measure of LV ejection fraction.8,19 Before cannulation
for CPB, we recorded baseline measurements of all hemodynamic
parameters, including cardiac output and a 1-minute TEE reading.
At 10 to 15 minutes after separation from CPB, all hemodynamic
and TEE measurements were repeated.
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LV Biopsy Specimens
Before CPB initiation, we collected a transmural biopsy specimen
from a fat-free area of the LV anterior wall by using a 14-gauge
biopsy needle (Gallini). A second LV biopsy specimen was taken
at the end of the extracorporeal circulation period before weaning
from CPB. All LV biopsy specimens were placed in 4% parafor-
TABLE 1. Baseline demographic and clinical characteristics of the trial groups
Characteristic NAC group (n  20) Placebo group (n  20)
Mean  SD age, y 66.2 11.8 66.5 6.5
Female sex, n (%) 8 (40) 1 (5)
Arterial hypertension, n (%) 17 (85) 16 (80)
Diabetes, n (%) 7 (35) 6 (30)
Smoking history, n (%) 9 (45) 7 (35)
Previous myocardial infarction, n (%) 6 (30) 10 (50)
Vessel disease, n (%)
1 1 (5) 0 (0)
2 3 (15) 4 (20
3 16 (80) 16 (80)
Mean  SD body mass index, kg/m2 27.3 4.4 27.8 3.7
Mean  SD angiographic LV ejection
fraction, %
57.9 16.7 (n 17)* 63.9 14.1 (n 17)*
Mean  SD LVEDP, mm Hg 15.5 8.3 (n 15)* 14.8 6.7 (n 13)*
Mean  SD LV 8-iso-prostaglandin-F2,
gray units
21.7 6.9 (n 17)† 19.0 5.6 (n 19)†
Mean  SD LV nitrotyrosine, gray units 45.7 11.4 (n 19)† 39.2 8.1 (n 18)†
Mean  SD cardiac index, l/min/m2 2.47 0.45 (n 19)‡ 2.55 0.47
Mean  SD FAC, % 63.1 11.0 (n 18)§ 61.0 11.3 (n 17)§
LVEDP, LV end-diastolic pressure. Reasons for missing values (n 20) are as follows: *not determined at the time of heart catheterization; †small LV biopsy
size (see also Figure 1); ‡Swan-Ganz-catheter placement impossible; §TEE not performed.
Figure 1. Flow chart depicting the phases of the trial according to the Consolidated Standards of Reporting Trials
(CONSORT) statement.18
Tossios et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1515
CS
P
maldehyde for 4 hours and then rinsed in 0.1 mol/L phosphate-
buffered saline (PBS) for 24 hours, followed by storage for 12
hours in PBS solution with 18% sucrose for cryoprotection and
frozen at 80°C.
Immunocytochemistry
Before immunohistochemical examination, 7-m slices from the
biopsy specimens were placed in a bathing solution of 3% H2O2
and methanol for 20 minutes, and then cells were lysed with 0.25%
Triton-X 100 in 0.5 mol/L ammonium chloride. Thereafter, spec-
imens were treated with 5% bovine serum albumin solution in 0.05
mol/L Tris-buffered saline. Before each step, the sections were
rinsed 3 times in 0.05 mol/L Tris-buffered saline buffer. For
nitrotyrosine staining, we used a monoclonal mouse anti-nitroty-
rosine antibody (1:400, Calbiochem) and a secondary goat anti-
mouse antibody (1:400, DAKO). For 8-iso-prostaglandin-F2 de-
tection, a polyclonal goat anti-8-Epi-PGF2 antibody (1:1500,
Oxford Biomedical Research) and a secondary rabbit anti-goat
antibody (1:400, DAKO) were used. A streptavidin–horseradish
peroxidase complex was then applied as a detection system (1:150)
for 1 hour. Finally, staining was developed for 10 to 20 minutes
with 3,3-diaminobenzidine tetrahydrochloride in 0.1 mol/L PBS.
8-Iso-prostaglandin-F2 and Nitrotyrosine Television
Densitometry
All LV biopsy slices were incubated and stored under identical
conditions. For quantitative intensity analyses of 8-iso-prostaglan-
din-F2 and nitrotyrosine immunostaining in cardiomyocytes, we
measured the gray values of 30 cardiomyocytes from 6 randomly
selected areas. The staining intensity was reported as the mean of
the measured cardiomyocyte gray value minus the background
gray value. The background gray value was measured at a cell-free
area of the slice. For staining intensity detection, a Zeiss Axiophot
microscope coupled to a 3-chip CCD camera was used, and the
analysis was performed by using the Optimas 6.01 image analysis
program installed on a Pentium PC.
Study Design
We conducted a randomized, double-blind, controlled clinical trial
to compare NAC versus placebo on ROS-mediated myocardial
injury in the hearts of patients subjected to coronary artery surgery
during CPB. Patients and study staff (including end point asses-
sors) were blinded to group assignment. Change (end of CPB 
before CPB) in 8-iso-prostaglandin-F2 (nitrotyrosine) density
was predefined in the trial protocol as the primary (coprimary) end
point for confirmatory statistical analysis (method of a priori–
ordered hypotheses).
On the basis of our previous study,8 in which we found that the
number of 8-iso-prostaglandin-F2–positive capillaries increased
by approximately 100% from before CPB to the end of CPB (from
92  72/mm2 before CPB to 209  108/mm2 at the end of CPB),
we assumed that compared with placebo, NAC would reduce the
increase in 8-iso-prostaglandin-F2–positive capillaries per square
millimeter by 50%. Thus a sample size of 20 patients per group
seemed adequate to ensure a power of at least 80% at a 2-tailed
significance level of 5%.
Statistical Analysis
Continuous variables were summarized as means  SD. Changes
in primary or secondary outcome variables were analyzed for
statistical significance at an  level of 5% by using either the
2-tailed Welch modified t test for unpaired samples (to account for
unequal variances in groups) or the Student t test for paired
samples, where appropriate. Corresponding 95% confidence inter-
vals (CIs) are given to allow assessment of effect sizes for clinical
relevance. Statistical analyses were performed with the software
package SPSS for Windows, Release 10.0.7. The P values reported
for the primary end points need not to be adjusted for multiple
testing because a fixed sequence of hypotheses was predefined in
the trial protocol.
Results
Immunostaining for 8-iso-prostaglandin-F2 and nitroty-
rosine in cardiac myocytes and capillaries is depicted in
Figure 2. Compared with conditions before CPB, LV car-
diac myocytes of the placebo group demonstrated 8-iso-
prostaglandin-F2 and nitrotyrosine formation at the end of
CPB. In contrast, cardiac myocytes of the NAC group
remained negative for both 8-iso-prostaglandin-F2 and ni-
trotyrosine at the end of CPB. Because of the small size of
the LV biopsy samples, we were able to densitometrically
quantitate cardiomyocyte staining for 8-iso-prostaglandin-
F2 (before CPB and at the end of CPB) in 19 patients of
the placebo group and 17 patients of the NAC group and for
nitrotyrosine in 18 patients of the placebo group and 19
patients of the NAC group, respectively. In the placebo
group 8-iso-prostaglandin-F2 staining increased from 19.0
 5.6 gray units before CPB to 24.0  6.6 gray units at the
end of CPB (P  .001; 95% CI for mean change, 3.0-6.9),
and nitrotyrosine staining increased from 39.2  8.1 gray
units before CPB to 48.3  12.1 gray units at the end of
CPB (P  001; 95% CI for mean change, 5.0-13.4). In the
NAC group the change in 8-iso-prostaglandin-F2 staining
was not statistically significant (21.7 6.9 gray units before
CPB and 19.8 4.1 gray units at the end of CPB; P .323;
95% CI for mean change, 5.7 to 2.0), and nitrotyrosine
staining actually decreased from 45.7  11.4 gray units
before CPB to 39.4  9.4 gray units at the end of CPB (P
 .012; 95% CI for mean change, 11.2 to 1.6). The
changes (from before CPB to the end of CPB) in cardio-
myocyte density for 8-iso-prostaglandin-F2 and nitroty-
rosine are depicted in Figure 3.
Intraoperative procedures and clinical outcomes were
similar between groups; there were no deaths or periopera-
tive myocardial infarctions (Table 2). We did not observe
adverse effects attributable to NAC. Post-CPB hemodynam-
ics, including heart rate, vascular pressures, systemic and
pulmonary vascular resistance, cardiac index, LV function
as measured by FAC, and positive inotropic medication,
were similar between groups. The summary results for each
study group are displayed in Table 3.
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Discussion
Our data show that ROS scavenging with NAC prevents
ROS-mediated myocardial stress induced by CPB and car-
dioplegic arrest because both 8-iso-prostaglandin-F2 and
nitrotyrosine formation in LV cardiac myocytes were sig-
nificantly lower in patients receiving NAC compared with
those seen in patients receiving placebo. These data for the
first time provide direct evidence that ROS scavenging
Figure 2. Immunostaining for 8-iso-prostaglandin-F2 and nitrotyrosine in cardiac myocytes and capillaries shows
that compared with conditions before CPB (A and E), LV cardiac myocytes of the placebo group demonstrated
8-iso-prostaglandin-F2 (B) and nitrotyrosine (F) formation at the end of CPB. In contrast, cardiac myocytes of the
NAC group (C and G) remained negative for both 8-iso-prostaglandin-F2 (D) and nitrotyrosine (H) at the end of CPB
(bar  35 m).
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attenuates oxidative stress in hearts of patients subjected to
ischemia and reperfusion induced by cardioplegic arrest.
Ischemia-reperfusion injury is a multifactorial process
involving physical, metabolic, and immunologic compo-
nents. It affects both cardiac myocytes and coronary endo-
thelial cells and appears to be a major factor contributing to
perioperative myocardial damage.20 Although the patho-
physiology of ischemia-reperfusion injury is not yet fully
understood, massive ROS production has been identified as
an important causative factor mediating the reperfusion
injury that characterizes metabolic, structural, and func-
tional myocardial damage associated with myocardial isch-
emia and reperfusion.1-3 During the ischemic period, aden-
osine triphosphate consumption leads to accumulation of
the purine catabolites hypoxanthine and xanthine, which, on
subsequent reperfusion and oxygen influx, are metabolized
by xanthine oxidase to produce massive amounts of super-
oxide and hydrogen peroxide.1 Furthermore, ischemia acts
as stimulus for constitutive NO synthase activation,21-23
resulting in increased NO release and subsequent ONOO
production during reperfusion.8 ROS then attack myocardial
phospholipids and proteins, leading to formation of 8-iso-
prostaglandin-F2, the stable end product of arachidonic
acid oxidation,6,9 and nitrotyrosine, the stable end product
of cell membrane protein–bound tyrosine nitration by
ONOO.10,11 We have previously demonstrated that isch-
emia and reperfusion induced by cardioplegic arrest resulted
in both 8-iso-prostaglandin-F2 and nitrotyrosine formation
in LV biopsy specimens of patients subjected to cardiac
surgery.8 These data provide a rational basis for clinical
investigation of ROS scavengers as adjuncts to myocardial
protection strategies.
However, only a few clinical studies have investigated
whether ROS scavenging ameliorates myocardial injury as-
sociated with CPB and cardioplegic arrest. Even though
these studies investigating ROS scavengers, such as defer-
oxamine,14 NAC,15 or allopurinol either alone7,13 or in
combination with vitamins E and C,12 have suggested indi-
rect evidence for beneficial effects, including reduced neu-
trophil oxidative burst response14,15 and improved patient
outcome,7,12,13 none of these studies directly investigated
the effect of ROS scavenging on myocardial tissue alter-
ations. In the present study the antioxidant and ROS scav-
enger NAC completely prevented myocardial 8-iso-prosta-
glandin-F2 formation induced by cardioplegic arrest and
subsequent reperfusion. To our knowledge, this is the first
study providing direct evidence that ROS scavenging atten-
uates oxidative stress in the hearts of patients subjected to
cardioplegic arrest. Interestingly, we found that cardiac
myocyte nitrotyrosine density actually decreased from be-
fore CPB to the end of CPB in the NAC group. This
indicates that at the time of the first LV biopsy, some
nitrotyrosine must have already been present, probably as a
result of nonspecific inflammatory ONOO production in-
duced by stress, the surgical trauma per se, or both.1 Thus to
yield the full potential benefit of its ROS-scavenging prop-
erties, NAC application should probably begin before an-
esthesia induction.
The functional correlate of ROS-mediated tissue injury is
myocardial stunning.2,3 Recent experimental studies have
shown that 8-iso-prostaglandin-F2 resulted in coronary
vasoconstriction associated with lactate production and con-
tractile dysfunction.24 This coronary vasoconstriction per-
sisted even after removal of the ROS stimulus and might
thus contribute to the no-reflow phenomenon during reper-
fusion.25 In addition, ONOO production caused by in-
creased NO release has been demonstrated to be associated
with irreversible cardiac function impairment26 and higher
mortality after coronary occlusion27 and might be involved
in cardiac apoptosis initiation.11 Finally, Gupte and Okada28
recently demonstrated in isolated rat hearts that ROS me-
diate LV dysfunction through ONOO production that can
be attenuated by NO synthase inhibition. In the present
study global LV ejection fraction, as measured on the basis
of FAC, cardiac index, and clinical patient outcome, was
similar between the NAC and placebo groups, and thus the
functional and clinical relevance of ROS scavenging re-
mains to be evaluated. However, cardiac performance di-
rectly determined after CPB might not reflect potential
long-term effects attributable to ROS, determination of
which is beyond the scope of the present acute study.
Considering the role of ROS in metabolic and structural
myocardial alterations, as well as cardiac apoptosis induc-
tion1 potentially impairing cardiac performance, attenuation
Figure 3. Change from before CPB to the end of CPB in cardio-
myocyte density for 8-iso-prostaglandin-F2 and nitrotyrosine in
both groups. Data are presented as means  SD (for 8-iso-
prostaglandin-F2, n  19 in the placebo group and n  17 in the
NAC group; for nitrotyrosine, n  18 in the placebo group and n
 19 in the NAC group).
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of ROS-mediated myocardial tissue alterations by NAC has
to be regarded as a cardioprotective measure.
In conclusion, the data of the present study for the first
time provide direct evidence that ROS scavenging with
NAC attenuates oxidative stress in the hearts of patients
subjected to CPB and cardioplegia. Because we did not
observe adverse effects attributable to NAC, our data indi-
cate that routine NAC administration might be a useful tool
to attenuate ROS-mediated myocardial stress in patients
undergoing cardiac surgery.
References
1. Droege W. Free radicals in the physiological control of cell function.
Physiol Rev. 2002;82:47-95.
2. Sekili S, McCay PB, Li X-Y, Zughaib M, Sun J-Z, Tang L, et al.
Direct evidence that the hydroxyl radical plays a pathogenetic role in
myocardial “stunning” in the conscious dog and demonstration that
stunning can be markedly attenuated without subsequent adverse ef-
fects. Circ Res. 1993;73:705-23.
3. Li X-Y, McCay PB, Zughaib M, Jeroudi MO, Triana F, Bolli R.
Demonstration of free radical generation in the “stunned” myocardium
in the conscious dog and identification of the major differences be-
tween conscious and open-chest dogs. J Clin Invest. 1993;92:1025-41.
TABLE 2. Perioperative characteristics and post-CPB hemodynamics of the trial groups
Characteristic NAC group (n  20) Placebo group (n  20)
Grafts, n (%)
1 1 (5) 0 (0)
2 1 (5) 5 (25)
3 10 (50) 9 (45)
4 7 (35) 5 (25)
5 1 (5) 1 (5)
ITA use, n (%) 20 (100) 18 (90)
Hospital mortality, n (%) 0 (0) 0 (0)
Perioperative myocardial infarction, n (%) 0 (0) 0 (0)
Mean  SD duration, min
Operation 175 25 157 20
CPB 80 19 73 18
Aortic crossclamp 43 10 38 9
Reperfusion 28 7 27 8
Mean  SD dopamine, g · kg1 · min1 4.2 1.6 4.2 1.4
Mean  SD postoperative CK, U/L 84.8 26.3 86.6 23.3 (n 19)*
Mean  SD postoperative CK-MB, U/L 13.0 3.7 10.3 3.9 (n 19)*
Mean  SD heart rate, beats/min 91.2 10.7 88.5 12.9
Mean  SD arterial pressure, mm Hg 69.0 8.5 70.0 9.2
Mean  SD PAP, mm Hg 15.7 5.8 (n 19)† 14.1 4.0
Mean  SD PCWP, mm Hg 9.8 5.3 (n 19)† 9.7 3.9 (n 19)‡
Mean  SD CVP, mm Hg 7.8 3.9(n 19)† 7.0 4.3
Mean  SD SVRI, dyn · s1 · m2/cm5 1516 471 (n 19)† 1325 256
Mean  SD PVRI, dyn · s1 · m2/cm5 143 75 (n 19)† 110 49 (n 18)§
ITA, Internal thoracic artery; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure; SVRI, systemic
vascular resistance index; PVRI, pulmonary vascular resistance index. Reasons for missing values (n  20) are as follows: *data not in patient chart; †no
Swan-Ganz-catheter; ‡no wedge position of Swan-Ganz catheter balloon; §calculation not possible because of no wedge position of Swan-Ganz catheter
balloon (n 1); one excluded because of negative value (pulmonary artery pressure  pulmonary capillary wedge pressure).
TABLE 3. Summary results for each study group
End point NAC group (n) Placebo group (n) Difference (95% CI)* P value*
Change† in 8-iso-prostaglandin-F2
 SD, gray units
1.8 7.5 (n 17) 5.0 4.1 (n 19) 6.8 (2.6 to 11.0) .003
Change† in nitrotyrosine  SD,
gray units
6.4 10.0 (n 19) 9.2 8.4 (n 18) 15.6 (9.4 to 21.7) .001
Change‡ in cardiac index  SD, L
· min1 · m2
0.94 0.83 (n 19) 1.32 0.71 (n 20) 0.39 (0.12 to 0.89) .128
Change‡ in FAC  SD, % 5.6 13.4 (n 18) 5.0 6.1 (n 17) 0.6 (7.8 to 6.6) .864
For reasons for missing values (n  20), see legends for Tables 1 and 2.
*Welch’s t test.
†Change  End of CPB  before CPB.
‡Change  after CPB  before CPB.
Tossios et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1519
CS
P
4. Davies SW, Ranjadayalan K, Wickens DC, Dorinandy TL, Tinunis
AD. Lipid peroxidation associated with successful thrombolysis. Lan-
cet. 1990;335:741-3.
5. Grech ED, Dodd HF, Bellamy CM, PERRY RA, Morrison WL,
Ramsdale DR. Free radical generation during angioplasty reperfusion
for acute myocardial infarction. Lancet. 1993;341:990-1.
6. Reilly MP, Delanty N, Roy L, Rokach J, Callaghan PO, Crean P, et al.
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prosta-
glandin F2alpha in acute coronary angioplasty: evidence for oxidant
stress during coronary reperfusion in humans. Circulation. 1997;96:
3314-20.
7. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, et
al. Allopurinol pretreatment improves postoperative recovery and re-
duces lipid peroxidation in patients undergoing coronary bypass graft-
ing. J Thorac Cardiovasc Surg. 1994;107:248-56.
8. Mehlhorn U, Krahwinkel A, Geissler HJ, Larosee K, Fischer UM,
Klass O, et al. Nitrotyrosine and 8-isoprostane formation indicate free
radical-mediated injury in hearts of patients subjected to cardioplegia.
J Thorac Cardiovasc Surg. 2003;125:178-83.
9. Basu S, Nozari A, Liu XL, Rubertsson S, Wiklund L. Development of
a novel biomarker of free radical damage in reperfusion injury after
cardiac arrest. FEBS Lett. 2000;470:1-6.
10. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA.
Peroxynitrite induced nitration and inactivation of myofibrillar creat-
ine kinase in experimental heart failure. Cardiovasc Res. 2001;49:798-
807.
11. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-
Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major
determinant of ventricular dysfunction and failure in dog dilated car-
diomyopathy. Circ Res. 2001;89:279-86.
12. Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I,
Tarkka M. Pretreatment with antioxidants and allopurinol diminishes
cardiac onset events in coronary artery bypass grafting. Ann Thorac
Surg. 1995;59:1519-23.
13. Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor
JW, et al. Allopurinol neurocardiac protection trial in infants under-
going heart surgery using deep hypothermic circulatory arrest. Pedi-
atrics. 2001;108:61-70.
14. Menasche P, Pasquier C, Belluci S, Lorente P, Jaillon P, Piwnica A.
Deferoxamine reduces neutrophil-mediated free radical production
during cardiopulmonary bypass in man. J Thorac Cardiovasc Surg.
1988;96:582-9.
15. Andersen LW, Thiis J, Kharazmi A, Rygg I. The role of N-acetylcys-
teine administration on the oxidative response of neutrophils during
cardiopulmonary bypass. Perfusion. 1995;10:21-6.
16. Kelly GS. Clinical application of N-acetylcysteine. Altern Med Rev.
1998;3:114-27.
17. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D,
Zideck W. Prevention of radiographic-contrast-agent-induced reduc-
tions in renal function by acetylcysteine. N Engl J Med. 2000;343:
210-2.
18. Moher D, Schulz KF, Altman DG, for the CONSORT group. The
CONSORT statement: revised recommendations for improving the
quality of reports of parallel-group randomised trials. Lancet. 2001;
357:1191-4.
19. Clements FM, Harpole DH, Quill T, Jones RH, McCann RL. Estima-
tion of left ventricular volume and ejection fraction by two-dimen-
sional transesophageal echocardiography: comparison of short axis
imaging and simultaneous radionuclide angiography. Br J Anesth.
1990;64:331-6.
20. Nonami Y. The role of nitric oxide in cardiac ischemia-reperfusion
injury. Jpn Circ J. 1997;61:119-32.
21. Bloch W, Mehlhorn U, Krahwinkel A, Reiner M, Dittrich M, Schmidt
A, et al. Ischemia increases detectable endothelial nitric oxide synthase
in rat and human myocardium. Nitric Oxide. 2001;5:317-33.
22. Depre´ C, Fierain L, Hue L. Activation of nitric oxide synthase by
ischaemia in the perfused heart. Cardiovasc Res. 1997;33:82-7.
23. Mehlhorn U, Bloch W, Krahwinkel A, LaRose K, Geissler HJ, Hekmat
K, et al. Activation of myocardial constitutive nitric oxide synthase
during coronary artery surgery. Eur J Cardiothorac Surg. 2000;17:
305-11.
24. Mobert J, Becker BF, Zahler S, Gerlach E. Hemodynamic effects of
isoprostanes (8-iso-prostaglandin F2alpha and E2) in isolated guinea
pig hearts. J Cardiovasc Pharmacol. 1997;29:789-94.
25. Gupte SA, Okada T, Tateyama M, Ochi R. Activation of TxA2/PGH2
receptors and protein kinase C contribute to coronary dysfunction in
superoxide treated rat hearts. J Mol Cell Cardiol. 2000;32:937-46.
26. Digerness SB, Harris KD, Kirklin JW, Urthaler F, Viera L, Beckman
JS, et al. Peroxynitrite irreversibly decreases diastolic and systolic
function in cardiac muscle. Free Radic Biol Med. 1999;27:1386-92.
27. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric
oxide synthase expression contributes to myocardial dysfunction and
higher mortality after myocardial infarction in mice. Circulation.
2001;104:700-4.
28. Gupte SA, Okada T. Prostaglandins and nitric oxide mediate super-
oxide-induced myocardial contractile dysfunction in isolated rat
hearts. J Mol Cell Cardiol. 2001;33:1107-17.
Cardiopulmonary Support and Physiology Tossios et al
1520 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
CSP
